NEW YORK, March 19 (GenomeWeb News) - The National Institute of Diabetes and Digestive and Kidney Diseases announced today that it will commit $1 million in FY 2005 to fund projects devoted to using proteomic and metabolomic techniques to develop a diagnostic for type 2 diabetes.
Applicants can request funding for two years under the R21 mec
In addition to funding, the NIDDK will provide to investigators plasma from diverse individuals for use in validation experiments. Plasma from three types of patients will be provided: those who have been diagnosed with type 2 diabetes; those who have impaired glucose tolerance, and those who have normal glucose tolerance.
The newest PAR is one of several that the NIDDK has issued over the past couple of years inviting investigators to apply proteomics to the study of diabetes.